Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Farnesyl diphosphate synthase pseudogene 6 (FDPSP6) is classified as a processed pseudogene in the human genome[1][6]. It is related to the functional enzyme farnesyl diphosphate synthase (FDPS), but FDPSP6 does not produce an active protein and does not participate in any known biological processes or disease mechanisms. Pseudogenes such as FDPSP6 typically arise from duplication or retrotransposition events and usually do not have therapeutic relevance, do not code for proteins, and are not considered therapeutic targets. FDPSP6 is a pseudogene, meaning it is a nonfunctional segment of DNA similar to a functional gene[1][6]. The functional gene, farnesyl diphosphate synthase (FDPS), encodes an enzyme of pharmacological and biological importance, but FDPSP6 does not retain this function[3][5][8]. There are no reported drugs, disease associations, or biomarker uses for FDPSP6[1][6]. There is no evidence that FDPSP6 is expressed or contributes to any molecular pathway or serves as a therapeutic target—hence, the entry is considered nonstandard as a "target" (is_incorrect: true).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Farnesyl diphosphate synthase pseudogene 6 (FDPSP6).